---
title: >-
  Real-world polypharmacy and healthcare resource utilization after early-line
  treatment with cannabidiol for Lennox-Gastaut syndrome, Dravet syndrome, and
  tuberous sclerosis complex
description: >-
  Explore this publication on real-world evidence: Real-world polypharmacy and
  healthcare resource utilization after early-line treatment with cannabidiol
  for…
date: '2026-01-01'
category: Publications
tags:
  - Jazz Pharmaceuticals
  - Poster Presentation
  - Pharma Partner
  - Approval & Commercialization
  - 'No'
  - Methods/Pharmacoepi
  - R&D
canonical_url: >-
  https://www.headwaterscience.com/resources/publications/ind-jazz-pharmaceuticals/real-world-polypharmacy-and-healthcare-resource-utilization/
source: Headwater Science
license: © 2026 Headwater Science. All rights reserved.
slug: real-world-polypharmacy-and-healthcare-resource-utilization
id: 6PySp7yEhXueic0zU2ps5F
contentType: article
---

## Challenge

Patients with treatment-resistant epilepsy initiating cannabidiol (CBD) therapy often remain on multiple antiseizure medications, but the real-world impact of CBD on polypharmacy burden and healthcare resource utilization had not been characterized beyond clinical trials.

## Solution

Target RWE researchers analyzed real-world data from early-line CBD-treated epilepsy patients to characterize changes in ASM polypharmacy and healthcare resource utilization following CBD initiation, funded by Jazz Pharmaceuticals.

## Impact

Demonstrating real-world reductions in ASM polypharmacy after CBD initiation provides Jazz Pharmaceuticals with post-market effectiveness evidence supporting label messaging and payer arguments for CBD as a polypharmacy-reducing add-on therapy.

## Use Cases / Links

CBD post-market effectiveness evidence for ASM polypharmacy reduction in epilepsy for Jazz Pharmaceuticals, Real-world HCRU evidence supporting cannabidiol label and payer strategy in treatment-resistant epilepsy